Donoghue Forlines’s Regeneron Pharmaceuticals REGN Stock Holding History

Donoghue Forlines’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-456	Closed	-$375K	–	271
2023 Q1	$375K	Sell	456 -45	-9%	-$33.9K	0.13%	173
2022 Q4	$361K	Sell	501 -208	-29%	-$153K	0.13%	183
2022 Q3	$488K	Sell	709 -1,616	-70%	-$1.02M	0.18%	103
2022 Q2	$1.37M	Buy	2,325 +1,091	+88%	+$709K	0.36%	54
2022 Q1	$862K	Buy	+1,234	New	+$781K	0.19%	175
2020 Q3	–	Sell	-2,308	Closed	-$1.44M	–	137
2020 Q2	$1.44M	Buy	+2,308	New	+$1.31M	0.38%	43
2019 Q2	–	Sell	-6,604	Closed	-$2.71M	–	205
2019 Q1	$2.71M	Buy	+6,604	New	+$2.72M	0.27%	57
2018 Q4	–	Sell	-6,631	Closed	-$2.68M	–	124
2018 Q3	$2.68M	Buy	+6,631	New	+$2.52M	0.21%	82

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Donoghue Forlines's REGN Position: Q2 2023 in Review

Donoghue Forlines sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 456 shares — an estimated $375K sold.

Donoghue Forlines first reported a position in REGN in Q3 2018 and held it in 8 quarters. The position peaked at $2.71M in Q1 2019. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Donoghue Forlines reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Donoghue Forlines sold 456 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $375K.
Donoghue Forlines first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Donoghue Forlines's Regeneron Pharmaceuticals position peaked at $2.71M in Q1 2019.
1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Donoghue Forlines's 13F filing for Q2 2023, filed 7 Aug 2023.